The efficacy of intravitreal bevacizumab for acute central serous chorioretinopathy

• Published in: Journal of ocular pharmacology and therapeutics Vol. 29; no. 1; p. 10
• Main Author: Aydin, Erdinc
• Format: Journal Article
• Language: English
• Published: United States 01.02.2013
• Subjects: Acute Disease; Adult; Angiogenesis Inhibitors - administration & dosage; Angiogenesis Inhibitors - therapeutic use; Antibodies, Monoclonal, Humanized - administration & dosage; Antibodies, Monoclonal, Humanized - therapeutic use; Bevacizumab; Central Serous Chorioretinopathy - drug therapy; Central Serous Chorioretinopathy - pathology; Female; Follow-Up Studies; Humans; Intraocular Pressure - drug effects; Intravitreal Injections; Male; Middle Aged; Recurrence; Time Factors; Tomography, Optical Coherence; Treatment Outcome; Visual Acuity - drug effects

To investigate the efficacy of intravitreal bevacizumab injection in patients with acute central serous chorioretinopathy (CSCR). Between 6 weeks and 3 months, 13 eyes of 22 patients with acute CSCR received an intravitreal bevacizumab injection (2 mg/0.08 mL), 9 eyes had no medical treatment as a c...